BRIEF-Ligand To Acquire Apeiron Biologics AG For $100 Million-March 2024-www.financetom.com

BRIEF-Ligand To Acquire Apeiron Biologics AG For $100 Million

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Ligand To Acquire Apeiron Biologics AG For $100 Million

Jul 8, 2024 5:26 AM

July 8 (Reuters) - Ligand Pharmaceuticals Inc ( LGND ):

* LIGAND TO ACQUIRE APEIRON BIOLOGICS AG FOR $100 MILLION

* LIGAND PHARMACEUTICALS INC ( LGND ) - LIGAND INCREASES 2024

ADJUSTED EPS

GUIDANCE RANGE BY 17% TO $5.00-$5.50

* LIGAND PHARMACEUTICALS ( LGND )- DEAL TO BE IMMEDIATELY ACCRETIVE

LIGAND EPS BY ESTIMATED $1.00 PER SHARE ON AN ANNUALIZED BASIS

WITH A $0.50 IMPACT TO 2024

* LIGAND PHARMACEUTICALS INC ( LGND ) - ACQUISITION PROVIDES LIGAND

WITH

ROYALTY RIGHTS TO QARZIBA®

* LIGAND PHARMACEUTICALS INC ( LGND ): INCREASING 2024 REVENUE

GUIDANCE TO

BE IN RANGE OF $140 MILLION TO $157 MILLION

Source text for Eikon:

Further company coverage:

Previous page： Chinese companies turn to generics as shipments behind US weight-loss craze fade Next page： FOCUS-Chinese companies turn to generics as shipments behind US weight-loss craze fade

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Chinese companies turn to generics as shipments behind US weight-loss craze fade

Sep 2, 2025

NEW YORK (Reuters) -Some Chinese companies now racing to make generic versions of Novo Nordisk's Wegovy also supplied ingredients for more than a billion makeshift doses of weight-loss drugs sold online in the U.S. over the past two years, according to three sources and a Reuters review of shipping and public records. Cheap copies of Wegovy and Eli Lilly's (...

FOCUS-Chinese companies turn to generics as shipments behind US weight-loss craze fade

Sep 2, 2025

* At least eight Chinese companies supplied raw ingredients for weight-loss drugs to US compounding pharmacies * In 2024, imports were enough for at least 1 billion starter doses * Novo's key semaglutide patent expires next year in Canada, Brazil * (Adds FDA comment in paragraph 26) By Patrick Wingrove NEW YORK, Sept 2 (Reuters) - Some Chinese companies now...

Google keeps Chrome and Apple deal but must share data in big antitrust ruling

Sep 2, 2025

(Reuters) -Google won't have to sell its Chrome browser, a judge in Washington said on Tuesday, handing a rare win to Big Tech in its battle with U.S. antitrust enforcers, but ordering Google to share data with rivals to open up competition in online search. Google parent Alphabet's shares were up 7.2% in extended trading on Tuesday as investors cheered...

PRESS DIGEST- Financial Times - September 3

Sep 2, 2025

Sept 3 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Thames Water creditors pledge more investment to try to seal rescue deal - US group's acquisition of top UK wealth managers heralds new consolidation push - Starmer considers digital ID rollout...